Elagolix Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 150 mg, 200 mg

Reference Brands: Orilissa (USA),

Category: Women's Health

Elagolix is available in Tablets and strengths such as 150 mg, 200 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Elagolix is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Elagolix can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Elagolix, marketed under the brand name Orilissa, is an oral gonadotropin-releasing hormone (GnRH) antagonist used primarily for the management of moderate to severe pain associated with endometriosis in women. By selectively blocking GnRH receptors in the pituitary gland, elagolix reduces the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to a dose-dependent decrease in ovarian estrogen production. This reduction in estrogen helps alleviate endometriosis-related pelvic pain, dysmenorrhea, and other associated symptoms.

Elagolix is administered orally once or twice daily, with treatment duration ranging from 6 to 24 months depending on the prescribed dosage and therapeutic goals. Beyond its approved use for endometriosis, elagolix is also under development for the treatment of uterine fibroids and heavy menstrual bleeding in premenopausal women. Earlier clinical investigations explored its potential use in men for prostate cancer and benign prostatic hyperplasia; however, these development programs have been discontinued.

With its targeted mechanism of action and oral dosing, elagolix provides a convenient and effective option for long-term management of estrogen-dependent gynecological conditions, offering symptom relief while allowing flexibility in dosing and duration of therapy.